Welcoming Excellence to Aspivix’s Board: Dr. Susan Nicholson and Jessica J. Federer
Epalinges, Switzerland – December 11, 2023 – Dr. Susan Nicholson & Jessica J. Federer join Aspivix’s Board of Directors alongside Keren Leshem, fortifying the Company’s Leadership in Women’s Health Care Innovation.
At Aspivix, a pioneering leader in women’s health, we believe in the power of expertise, innovation, and collaboration. That’s why we are thrilled to introduce two industry trailblazers joining our board of Directors: Dr. Susan Nicholson and Jessica J. Federer.
This strategic augmentation of the board with their expertise heralds a new era in Aspivix’s commitment to transforming women’s health care.
Dr. Susan Nicholson: Championing Change in Women’s Health
Dr. Susan Nicholson, our new esteemed chair of the board, is a fearless disruptor with a passion for healthcare innovation. With over 25 years of experience in biotech, big pharma, medical devices, and consumer health, Dr. Nicholson’s impact on women’s health, particularly in addressing the maternal mortality crisis, is both significant and inspiring. Her unwavering dedication and expertise align seamlessly with our mission to provide high-quality and equitable healthcare solutions.
Jessica J. Federer: Strategic Leader and Industry Convener
Jessica Federer, an experienced board member and former Chief Digital Officer of Bayer A.G., also joins Aspivix’s Board of Directors. She is recognized as an icon in digital health and emerging innovations, with a focus on deploying technology for meaningful advancements in business and society. Jessica is committed to increasing investment in innovations to modernize women’s health.
A Bright Future Ahead
As we look ahead, we couldn’t be more excited about the future of Aspivix. We are honored to have these distinguished top women experts join us on this journey and look forward to the positive impact they will undoubtedly make.
”We are very excited and confident that Dr. Susan Nicholson and Jessica J. Federer with their wealth of experience, unwavering expertise, and profound commitment to advancing women’s health, that perfectly resonate with our mission and will significantly contribute to Aspivix’s continued success”, says Mathieu Horras, our CEO.
Adding these two experts in Women’s health to our gender-equal board that includes Keren Leshem, CEO of OCON Therapeutics, underscores Aspivix’s dedication to diverse leadership and innovative thinking.
Together, their combined expertise and vision are expected to shape the future of Aspivix and to drive significant advancements in women’s health.
Join us in welcoming Dr. Nicholson and Jessica J. Federer as they embark on this exciting journey with us. Stay tuned for more updates at www.aspivix.com.
+1 (909) 808-1948
Share this story: